Biomea Fusion (BMEA) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Biomea Fusion (BMEA) over the past year, gaining 40.0% versus a loss of 20.7%. Over five years, BMEA leads with a -88.2% price change compared with -88.8% for PDSB. Biomea Fusion is the larger company by market cap ($102.7 million vs $100.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | PDSB |
|---|---|---|
| Share price | $1.42 | $1.38 |
| Market cap | $102.67M | $100.01M |
| 1-day change | +3.65% | +35.29% |
| YTD return | +14.52% | +79.22% |
| 1-year return | -20.67% | +39.96% |
| 5-year return | -88.22% | -88.81% |
| EPS (TTM) | $-0.30 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $1.55 |
| 52-week low | $0.872 | $0.195 |
| Distance from 52-week high | -36.52% | -10.97% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +392.96% | +262.32% |
| Average volume | 1.49M | 23.24M |
| Shares outstanding | 72.30M | 72.47M |
| Employees | 37 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed BMEA by 60.6 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
BMEA vs PDSB FAQ
Which is bigger, Biomea Fusion or PDS Biotechnology?
Biomea Fusion (BMEA) is larger, with a market capitalization of $102.67M compared with $100.01M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, BMEA or PDSB?
PDSB returned +39.96% over the past 12 months, compared with -20.67% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.